A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Part of paid clinical trials in Scottsdale, Arizona.

Sponsor
C4 Therapeutics, Inc.
Study ID
NCT07284758
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Cemsidomide — DRUG
    dosed orally (PO) once a day (QD) 14 days on/14 days off for each 28-day cycle
  • Dexamethasone — DRUG
    dosed PO once a week (QW) on Days 1, 8, 15, and 22 for each 28-day cycle

Study Details

This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

Key Dates

First listed
Dec 16, 2025
Start date
Feb 18, 2026
Status verified
Jun 2026
Primary completion
Mar 31, 2030
Completion
Mar 31, 2030

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cemsidomide + Dexamethasone:
    Participants receive cemsidomide plus dexamethasone during a 28-day treatment cycle, and will continue to receive treatment until the participant meets one of the discontinuation criteria.

Primary Outcome Measure

Overall response rate (ORR) per International Myeloma Working Group (IMWG) Response Criteria by an Independent Review Committee (IRC) [ Time Frame: up to approximately 43 months ]

Central Contacts

Locations (10)

FacilityCityStateZIPSite coordinators
HonorHealthScottsdaleArizona85258
Rizwan Khawaja, MD
Berenson Cancer CenterWest HollywoodCalifornia90069
James Berenson, MD
Winship Cancer Institute, Emory UniversityAtlantaGeorgia30322
Nisha Joseph, MD
Indiana University HealthIndianapolisIndiana46202
Attaya Suvannasankha, MD
START MidwestGrand RapidsMichigan49546
Andrew Sochacki, MD
Washington University/Siteman Cancer CenterSt LouisMissouri63108
Mark Schroeder, MD
University of Nebraska Medical CenterOmahaNebraska68198
Sarah Holstein, MD
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
Hamza Hashmi, MD
START San AntonioSan AntonioTexas78229
Kyriakos Papadopoulos, MD
University of Wisconsin - Carbone Cancer CenterMadisonWisconsin53792
Natalie Callander, MD

Find similar trials in Scottsdale, AZ

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
HonorHealth· Scottsdale, AZBerenson Cancer Center· West Hollywood, CAWinship Cancer Institute, Emory University· Atlanta, GAIndiana University Health· Indianapolis, INSTART Midwest· Grand Rapids, MIWashington University/Siteman Cancer Center· St Louis, MO

Related Studies